Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Emma C. Fink(Broad Institute), Benjamin L. Ebert(Dana-Farber Cancer Institute), Namrata D. Udeshi(Harvard University), Andrew A. Guirguis(Peter MacCallum Cancer Centre), Tanya Svinkina(Broad Institute), Steven A. Carr(Broad Institute), Andrew Nguyen(Broad Institute), Saurav D. Haldar(Broad Institute), Marie McConkey(Broad Institute), Michelle Chen(Broad Institute), Brian Liddicoat(Broad Institute), James A. Kennedy(The University of Adelaide), D.R. Mani(Broad Institute)
Cited by 126


Related Papers